Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-08

Clinical Trial Update: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating regorafenib eye drops for neovascular age-related macular degeneration was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2016-09-08